World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website http://www.wjon.org

Original Article

Volume 1, Number 3, June 2010, pages 111-117

Correlation Between Anthropometric Measures and Biomarker Changes After Neoadjuvant Therapy With Tamoxifen or Anastrozole in Postmenopausal Women With Breast Cancer

Figures

Figure 1.
Figure 1. Body mass index (BMI, kg/m2) versus Lymph node metastases (%).
Figure 2.
Figure 2. Estrogen receptor (ER) positivity in the anastrozole (A), placebo (P) and tamoxifen (T) groups pre- and post-treatment.
Figure 3.
Figure 3. Progesterone receptor (PgR) positivity in the anastrozole (A), placebo (P) and tamoxifen (T) groups pre- and post-treatment.
Figure 4.
Figure 4. Proliferative index (Ki-67) positivity in the anastrozole (A), placebo (P) and tamoxifen (T) groups pre- and post-treatment.
Figure 5.
Figure 5. Waist circumference (WC, cm ) versus Progesterone receptor (PgR) positivity after anastrozole treatment.
Figure 6.
Figure 6. Hip circunference (HC, cm) versus Progesterone receptor (PgR) positivity after anastrozole treatment.

Table

Table 1. Clinical Characteristics of the Study Population
 
VariableNMeanSDMinimumMedianMaximum
N: number of participants; SD: standard deviation; BMI: body mass index; HC: hip circumference; WC: waist circumference; WFR: waist-to-hip ratio.
Age (years)5766.259.95426787
Tumor size (cm)574.001.062.548
Menarche (years)5613.001.6891316
Menopause (years)5648.045.43395060
Parity (number of children)573.333.290313
Height (cm)57156.756.39139156169
Weight (kg)5769.2615.824069.5120
BMI (kg/m2)5728.186.2316.628.653.3
HC (cm)57101.2210.9079102128
WC (cm)5797.1115.486897160
WHR570.960.090.81.01.4